Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Share on Pinterest Cannabis derivatives may lead to new treatments for ovarian cancer. Image Credit: Bloomberg Creative Photos/Getty Images Early lab research shows that two cannabis compounds, THC ...

SAN ANTONIO -- The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for ...

Please provide your email address to receive an email when new articles are posted on . Sacituzumab govitecan did not improve PFS in HR-positive, HER2-negative breast cancer after endocrine therapy.

Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or ...

SAN ANTONIO – Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy ...

The antibody-drug conjugate sacituzumab govitecan (Trodelvy) did not improve progression-free survival among patients with endocrine-refractory hormone receptor (HR)+/HER2- advanced breast cancer when ...

Medical oncologist Dr. Komal Jhaveri presented results from a clinical trial testing a drug known as an antibody-drug conjugate, which delivers a chemotherapy payload more precisely to breast cancer ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine ...

Christiane Amanpour has been diagnosed with cancer again. The 67-year-old chief international anchor for CNN shared the news on Hannah Vaughan Jones’s podcast, Changing the Ovarian Cancer Story.